BRAIN SCIENTIFIC INC - BRSF STOCK NEWS

Brain Scientific (OTCQB:BRSF) announced that Brainbox, a leading Contract Research Organization, has successfully tested its NeuroCap technology. The positive evaluation indicates that the NeuroCap will be integrated into Brainbox's sports medicine and pharmaceutical solutions, enhancing their non-invasive brain stimulation research capabilities. CEO Hassan Kotob expressed excitement over the validation from such a respected organization.

This collaboration aims to propel advancements in neuroscience and medical research while widening Brain Scientific's footprint in the healthcare sector.

Brain Scientific (OTCQB:BRSF) has announced a new distribution agreement with SysteMedic to meet the rising demand for its FDA-cleared, CE Mark-approved NeuroCap device. This partnership targets both pediatric and ICU markets in Israel, where SysteMedic will utilize the NeuroCap for two new studies. The integration of SysteMedic follows a recent partnership with MVAP Medical Supplies, enhancing Brain Scientific’s global distribution efforts. The NeuroCap is positioned as a game-changer in neurodiagnostic wearables, with significant international interest after its CE certification.

Brain Scientific (OTCQB:BRSF) announces a new distribution agreement with MVAP Medical Supplies to enhance sales in the pediatric EEG market. The partnership aims to promote Brain Scientific's NeuroCap™, which simplifies EEG setup and improves patient comfort, addressing the needs of pediatric care. This collaboration follows recent partnerships with Fulcrum and D&D Medical, supporting Brain Scientific's goal of becoming a leader in the medical wearables sector. The company continues to innovate in neurology and precision motion technology.

Brain Scientific (OTCQB:BRSF) has announced a new distribution agreement with Fulcrum to enhance its sales strategy and brand awareness. The company will also benefit from the expertise of Kevin Winterfield, who joins as vice president of marketing and communications, aiming to accelerate growth in the medical wearables sector. Following key milestones, such as securing the CE Mark for its innovative NeuroCap device, Brain Scientific plans to expand its distribution network significantly in strategic markets.

Brain Scientific (OTCQB:BRSF) announced the immediate release of an improved NeuroCap device and a new distribution partnership with D&D Medical, Inc. for selling neurology devices in Tennessee, Kentucky, Indiana, and West Virginia. Enhancements to the NeuroCap include proprietary gel for better conductivity and improved adhesive pads, aiming to improve EEG testing efficiency. The NeuroCap is FDA 510k cleared for clinical use, facilitating quicker EEG preparations and expanding access to testing across various environments, including rural hospitals and private practices.

Brain Scientific announces the appointment of Daniel Cloutier as Chief Revenue Officer (CRO), aimed at advancing the company's initiatives in the medical technology sector. Cloutier, with significant experience in sales strategy and distribution, previously founded LOK Corporation and held positions at CAS Medical System. His leadership is expected to enhance sales and marketing efforts, positioning Brain Scientific for accelerated growth in the medical industry. CEO Hassan Kotob emphasizes the potential for rapid revenue growth and the importance of this strategic hire.

Brain Scientific, a Florida-based medical device company, has received the Conformité Européenne (CE) Mark for its NeuroCap™, enabling the commercialization of its neurological devices in Europe. This approval confirms compliance with the European Medical Device Directive, addressing strong demand from European neurologists. NeuroCap™ simplifies EEG tests with its pre-gelled electrodes and can be utilized in various clinical environments. The company aims to increase market penetration in Europe, enhancing access to EEG testing for patients.

Brain Scientific (OTCQB: BRSF) has finalized agreements to sell senior secured convertible debentures and warrants, aiming to raise approximately $5.1 million before fees. The debentures, with a principal amount of $5.6 million and a 10% annual interest rate, have a 12-month term and will convert during a qualified financing. Existing convertible notes worth $12.9 million will also convert into shares, fully incentivizing current investors. The private placement targets accredited investors and the Company plans to file a registration statement with the SEC.

Piezo Motion, a subsidiary of Brain Scientific (OTCQB:BRSF), has teamed up with DHM in Brazil to provide innovative motion control solutions. This partnership aims to deliver precision motor technology at lower costs to industries in Brazil and South America that specialize in electronic components. Piezo Motion’s advanced rotary and linear motors offer unmatched speed and accuracy, enhancing applications in laboratory instrumentation, biomedicine, and industrial systems. The collaboration is expected to drive significant advancements for product engineers and innovators in Brazil.